Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study

References

• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123–31.
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risk of cardiovascular disease. Am Heart J 2005;150:1115–21.
   PubMed Web of Science ®Google Scholar
• Ösby U, Correia N, Brandt L, Ekbom A, Sparén P. Time trends in schizophrenia mortality in Stockholm County, Sweden: Cohort study. BMJ 2000;321:483–4.
   Google Scholar
• Henderson DC. Weight gain with atypical antipsychotics: Evidence and insights. J Clin Psychiatry 2007;68 Suppl 12:18–26.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clin Psychiatry 2007;68 Suppl 1:20–27.
   PubMed Web of Science ®Google Scholar
• March JS, Silva SG, Compton S, Shapiro M, Califf R, Krishnan R. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005;162:836–46.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC, Nashrallah HA, Davis SM, Sullivan L, . Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Res 2005;80:19–32.
   PubMed Web of Science ®Google Scholar
• Birkenaes AB, Søgaard AJ, Engh JA, Jonsdottir H, Ringen A, Engh JA, . Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population. J Clin Psychiatry 2006;67:425–33.
   PubMed Web of Science ®Google Scholar
• Kahn R, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, . Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomized clinical trial. Lancet 2008;371:1085–97.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76.
   PubMed Web of Science ®Google Scholar
• World Health Organization. International statistical classification of diseases and related health problems, 10th revision, version for 2007. World Health Organization/German Institute of Medical Documentation and Information; 1994/2006. http://www.who.int/classifications/apps/icd/icd10online/. Accessed November 2, 2008.
   Google Scholar
• Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, . Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 2003;290:2693–702.
   PubMed Web of Science ®Google Scholar
• Bowen J, Hirsch S. Recruitment rates and factors affecting recruitments for a clinical trial of a putative anti-psychotic agent in the treatment of acute schizophrenia. Hum Psychopharmacol 1992;7:337–41.
   Web of Science ®Google Scholar
• Robinson D, Woerner M, Pollack S, Lerner C. Subject selection biases in clinical trials: Data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol 1996;16:170–6.
   PubMed Web of Science ®Google Scholar
• Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol 2000;20:699–702.
   PubMed Web of Science ®Google Scholar
• Drake RE, Rosenberg SD, Mueser KT. Assessing substance use disorder in persons with severe mental illness. New Dir Ment Health Serv 1996;70:3–17.
   PubMedGoogle Scholar
• Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophrenia Res 1990;3:247–51.
   PubMed Web of Science ®Google Scholar
• Karterud S, Pedersen G, Loevdahl H, Friis S. Global Assessment of Functioning—Split Version (S-GAF): Background and scoring manual. Oslo: Ullevaal University Hospital, Department of Psychiatry; 1998.
   Google Scholar
• Guy W. EDDEU Assessment Manual for Psychopharmacology—Revisited (DHHS publ NO ADM 91–338). Rockville, MD: US Department of Health and Human Services; 1976.
   Google Scholar
• Holmen J, Midthjell K, Krüger Ø, Langhammer A, Holmen TL, Bratberg GH. The Nord-Trøndelag Health Study 1995–97 (HUNT 2): Objectives, contents, methods and participation. Norsk Epidemiologi 2003;13:19–32.
   Google Scholar
• Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15:539–53.
   PubMed Web of Science ®Google Scholar
• Third report of the National Cholesterol Education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143–421.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB, Cleeman JI, Smith SJr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Arterioscler Thromb Vasc Biol 2004;24:e13–e18.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, . Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case–control study. Lancet 2004;364:937–52.
   PubMed Web of Science ®Google Scholar
• Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, . Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001;103:1245–9.
   PubMed Web of Science ®Google Scholar
• Weinehall L, Öhgren B, Persson M, Stegmayr B, Boman K, Hallmans G, . High remaining risk in poorly treated hypertension: The ‘rule of halves’ still exists. J Hypertens 2002;20:2081–88.
   PubMed Web of Science ®Google Scholar
• Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, . Recommendations for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurement in humans: A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on high blood pressure research. Circulation 2005;111:697–716.
   PubMed Web of Science ®Google Scholar
• Netea RT, Lenders JWM, Smits P, Thien T. Influence of body and arm position on blood pressure readings: An overview. J Hypertens 2003;21:237–41.
   PubMed Web of Science ®Google Scholar
• Lund-Larsen PG. Blood pressure measured with a sphygmomanometer and with Dinamap under field conditions—A comparison. Nor J Epidemiol 1997;7:235–41.
   Google Scholar
• Bovet P, Hungerbuhler P, Quilindo J, Grettve ML, Waeber B, Burnand B. Systematic difference between blood pressure readings caused by cuff type. Hypertension 1994;24:786–92.
   PubMed Web of Science ®Google Scholar
• Fodnesbergene G, Smoking in Norway, 2008. Steady decline in number of daily smokers. Statistics Norway 2009. http://www.ssb.no/english/subjects/03/01/royk_en/. Accessed February 12, 2009.
   Google Scholar
• World Health Organization Regional Office for Europe. Tobacco-free Europe. World Health Organization 2009. http://www.euro.who.int/tobaccofree/projects/20090209_3. Accessed March 06, 2009.
   Google Scholar
• Ramm J, Mindre røyking, men mer overvekt. Statistics Norway 2009. http://www.ssb.no/vis/magasinet/slik_lever_vi/art-2004-01-22-01.html. Accessed February 12, 2009.
   Google Scholar
• Statistics Norway 2009. StatBank Norway. Health, social conditions, social services and crime. Health conditions. Survey of level of living, health conditions. Lifestyle habits, by sex and age (percent) (1998–2005). http://statbank.ssb.no//statistikkbanken/default_fr.asp?PLanguage=1. Accessed February 12, 2009.
   Google Scholar
• De Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: A review. World Psychiatry 2009;8:15–22.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Stahl. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119:4–14.
   PubMed Web of Science ®Google Scholar
• Schorr SG, Slooff CJ, Bruggeman R, Taxis K. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res 2009; 43:1106–11.
   PubMed Web of Science ®Google Scholar
• Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study. Schizophrenia Res 2007;90:162–73.
   PubMed Web of Science ®Google Scholar
• De Hert M, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, . Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: A cross-sectional study. Clin Pract Epidemiol Ment Health 2006;2:14.
   PubMedGoogle Scholar
• De Hert M, Schreurs V, Sweers K., Van Eyck D, Hanssens L, Šinko S, . Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophrenia Res 2008;101:295–303.
   PubMed Web of Science ®Google Scholar
• van Winkel R, van Os J, Celic I, Van Eyck D, Wampers M, Scheen A, . Psychiatric diagnosis as an independent risk factor for metabolic disturbances: Results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008;69:1319–27.
   PubMed Web of Science ®Google Scholar
• Strand BH, Tverdal A. Can cardiovascular risk factors and lifestyle explain the educational inequalities in mortality from ischaemic heart disease and from other heart diseases? 26 year follow up of 50 000 Norwegian men and women. J Epidemiol Community Health 2004;58:705–9.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophrenia Res 2004;70:1–17.
   PubMed Web of Science ®Google Scholar
• Frayne SM, Halanych JH, Miller DR, Wang F, Liu H, Pogach L, . Disparities in diabetes care. Impact of mental illness. Arch Intern Med 2005;165:2631–8.
   PubMed Web of Science ®Google Scholar
• Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066–76.
   PubMed Web of Science ®Google Scholar
• Gothefors D, Adolfsson R, Attvall S, Erlinge D, Jarbin H, Lindström K, . Swedish Clinical Guidelines—Prevention and management of metabolic risk in patients with severe psychiatric disorders. Nord J Psychiatry; in press.
   Web of Science ®Google Scholar
• De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ, Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412–24.
   Google Scholar